$188 Million is the total value of Asymmetry Capital Management, L.P.'s 24 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 112.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $15,703,000 | – | 177,741 | +100.0% | 8.34% | – |
| HZNP | Buy | HORIZON THERAPEUTICS PLC | $14,829,000 | +442.6% | 137,610 | +451.6% | 7.87% | +379.1% |
| UNH | New | UNITEDHEALTH GROUP INC | $13,479,000 | – | 26,844 | +100.0% | 7.16% | – |
| ABBV | New | ABBVIE INC | $12,788,000 | – | 94,448 | +100.0% | 6.79% | – |
| IQV | New | IQVIA HOLDINGS INC | $12,503,000 | – | 44,314 | +100.0% | 6.64% | – |
| CNC | New | CENTENE CORP | $12,216,000 | – | 148,254 | +100.0% | 6.48% | – |
| BLU | Buy | BELLUS HEALTH INC | $10,310,000 | +56.5% | 1,280,757 | +19.4% | 5.47% | +38.2% |
| JNJ | New | JOHNSON & JOHNSON | $9,538,000 | – | 55,755 | +100.0% | 5.06% | – |
| NTRA | New | NATERA INC | $9,495,000 | – | 101,674 | +100.0% | 5.04% | – |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $8,278,000 | +32.6% | 716,709 | +9.6% | 4.39% | +17.0% |
| ARGX | New | ARGENX SE - ADRadr | $7,312,000 | – | 20,881 | +100.0% | 3.88% | – |
| KURA | Buy | KURA ONCOLOGY INC | $7,032,000 | +93.2% | 502,275 | +158.5% | 3.73% | +70.6% |
| APLS | New | APELLIS PHARMACEUTICALS INC | $6,593,000 | – | 139,445 | +100.0% | 3.50% | – |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $6,436,000 | -13.4% | 43,876 | +4.5% | 3.42% | -23.5% |
| ISEE | Buy | IVERIC BIO INC | $6,287,000 | +8.9% | 375,989 | +5.8% | 3.34% | -3.8% |
| ITOS | Buy | ITEOS THERAPEUTICS INC | $4,877,000 | +215.3% | 104,755 | +82.9% | 2.59% | +178.4% |
| RGLS | Buy | REGULUS THERAPEUTICS INC | $860,000 | -11.2% | 2,731,044 | +94.9% | 0.46% | -21.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-01-19
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.